clear cell sarcomas, 4 myxofibrosarcomas, 3 alveolar soft part sarcomas, 3 parachordoma/myoepiheliomas, 2 extraskeletal myxoid chondrosarcomas, 2 low grade fibromyxoid sarcomas were included in the study. Bone tumors, such as osteosarcomas and chondrosarcomas, and mesenchymal tumors with indolent clinical behavior, such as atypical lipomatous tumor/well differentiated liposarcoma were excluded.
representative areas were selected and 3-4 mm diameter tissue microarrays were composed from paraffin blocks. Microarray slides were stained for PD-L1 antibody (Cell Signaling, e1L3n®, 1/400) using Leica Bond Autostainer, according to the manufacturer's instructions. Antigen retrieval was performed with eDTA pretreatment for 20 minutes. Any membranous staining over 5% of the cells was regarded as positive. PD-L1 expression in tumor infiltrating inflammatory cells was also noted.
Quantitative real-time PCr with Fast-Plus evaGreen Master Mix (Cat no:31020, Biotium) and gene expression assays for CD274 was performed using whole sections from FFPe tissue of CD274 positive cases, by normalizing absolute values to β-actin. Total rnA was extracted using Hybrid-r rnA purification kit (GeneAll Biotechnology Co. Ltd.) according to the manufacturer protocol. rnA samples were quantified using the highly sensitive Qubit quantitation assays (Thermo Fisher Scientific). equal amounts of rnA were reverse transcribed using a HyperScript TM reverse Transcriptase (GeneAll Biotechnology Co. Ltd.) with oligod (T) primers according to the manufacturer's instruction (Table I ) PCr was performed with Fast-Plus evaGreen gene expression master mix, cDnA, nuclease free water, forward and reverse primers in a 20µl final reaction volume. The amplification cycles were performed by the rotor Gene -Q System (Qiagen) as follows, hold at 95°C for 3 min, followed by amplification for 40 cycles, each cycle consisting of denaturation at 95°C for 5 s, annealing at 55°C for 30 s. The housekeeping gene β-actin (Table I ) expression level was used as an internal control to evaluate the integrity of each sample. relative expression level of mrnA of PDL1 was calculated and scored using Log 10 2 (threshold cycle of b-actin -threshold cycle of PDL1) . relative expression was scored on a log10 scale (0-2). (Figure 1 ). Solitary fibrous tumor/hemangiopericytomas (n=18), desmoplastic round cell tumors (n=14), ewing-like sarcomas (n=6), epithelioid hemangioendotheliomas (n=5), clear cell sarcomas (n=4), myxofibrosarcomas (n=4), and low-grade fibromyxoid sarcomas (n=2) were all negative. 
Results

Genes
Primers β-actin (forward) AGAGCTACGAGCTGCCTGAC β-actin (reverse) AGCACTGTGTTGGCGTACAG CD274 (forward) AGGGCATTCCAGAAAGATGAG CD274 (reverse) TGTTCTTATCCTCCATTTCCCA Figure 3) . none of the cases showed >2 log mrnA expression.
DIsCussIoN
With this sarcoma series investigating PD-L1 expression with 222 cases, we have shown that a small subset (~15%) of sarcomas express PD-L1 in neoplastic cells. The highest PD-L1 expression among sarcomas was reported from the PD-L1 expression in tumor infiltrating inflammatory cells was present in 32 of 222 (14.4%) sarcomas (Figure 2A-C) . Only 4 of 34 (11.8%) PD-L1 positive sarcomas, 3 of which were dedifferentiated liposarcomas, also had PD-L1 positive inflammatory cells within the neoplasm (Table III) .
Quantitative real-time PCr revealed that 16 of 34 (47%) cases showed significant (>1 log) but low-level PD-L1 , that used DAkO antibody with 1% cutoff, Cell Signaling antibody with 5% cut-off, and Acris Antibody with 5% cut-off, respectively. We believe that a relatively lower figure of 6% by Inaguma et al. is mainly due to the absence of cases diagnosed as undifferentiated pleomorphic sarcomas and dedifferentiated liposarcomas in their series (11) .
Malignant mesenchymal tumors showing predominantly pleomorphic morphology, such as undifferentiated pleomorphic sarcomas, malignant peripheral nerve sheath tumors, and dedifferentiated liposarcomas demonstrated more PD-L1 expression (over 30% of the cases) than other types of sarcomas. In line with this, in a study including 53 MPnSTs, 13% were shown to express PD-L1 in tumor cells (15) , while in others 25% and 21% of MPnSTs were PD-L1 positive (11, 14) . Some studies also confirmed a significant correlation between PD-L1 expression and advanced clinicopathological parameters, such as higher clinical stage, presence of distant metastasis, as well as higher histological grade, poor differentiation of tumor, and tumor necrosis (8, 9) . Moreover, both PD1-and PD-L1 positivity were reported to be independent prognostic factors for overall survival by multivariate analysis; cases with a PD1+/PD-L1+ phenotype had the worst prognosis, which may benefit from PD1-based immunotherapy (8, 9) . Besides, few low-grade sarcomas, such as myxoid liposarcoma without a high-grade round cell component also showed PD-L1 expression. knowing ththat chemotherapy and radiotherapy has very limited effect on low grade sarcomas, anti-PD-L1 treatment may be the best option to prevent progression in metastatic low grade sarcomas showing PD-L1 expression. Larger series are required to assess the prevalence of PD-L1 expression among extraskeletal myxoid chondrosarcomas, alveolar soft part sarcomas, and parachordoma/myoepitheliomas as PD-L1 was positive in a significant percent of the low number of cases. Unfortunately, various sarcoma types including solitary fibrous tumor/hemangiopericytoma, desmoplastic round cell tumor, ewing-like sarcoma, epithelioid hemangioendothelioma, clear cell sarcoma, myxofibrosarcoma, and low-grade fibromyxoid sarcoma, many of which are high-grade by definition, did not express PD-L1, thus having less potential to benefit from anti-PD-L1 therapies.
expression of PD-L1 in tumor-infiltrating lymphocytes and macrophages was previously documented in sarcomas in detail (8, 12) . Inflammatory cells are present in almost all of the sarcomas, and 30% of lymphocytes and 58% of macrophages expressed PD-L1 (12). Paydas et al. also recorded that 30% of cells forming tumor microenvironment expressed PD-L1 (14) . Our result of 14.4% PD-L1 positive tumor-infiltrating inflammatory cells seems to be lower than expected, possibly due to the use of tissue microarrays instead of whole sections. We found a very low level (4%) of co-expression of PD-L1 in both tumor and tumor infiltrating inflammatory cells. In the series of Paydas et al., 21% of the sarcomas showed PD-L1 expression in both the tumor microenvironment and tumor cells; and kaposi sarcoma, not surprisingly, was the most common sarcoma with 80% of the cases showing this phenotype (14) . This high level of co-expression could be attributed to the phenomenal role of the immune system on the development and regression of this tumor.
Previously, PD-L1 expression was also demonstrated in both mrnA and protein level in a subset of osteosarcomas (7) . In their study, 9 samples had high-level expression (24%) with over 3 log fold increase, 19 samples (50%) had 
